Personalizing treatments to account for genetically mediated differences in drug responses is an exciting opportunity to improve patient outcomes. In this issue, Soccio et al. reveal new mechanisms by which non-coding variants alter the activity of the anti-diabetic drug rosiglitazone.
PPARg, a member of the class of ligandresponsive transcription factors (TFs) known as nuclear receptors, is a major driver of lipid uptake and adipogenesis. Small-molecule pharmaceuticals targeting PPARg have proven to be effective anti-diabetic agents. Although some individuals respond well to those treatments without adverse effects, others experience reduced efficacy and substantial side effects. That heterogeneity in treatment response poses a major limitation for treating type 2 diabetes and is representative of the broader challenges facing physicians when prescribing drugs that target other nuclear receptors.
Drug responses are highly heritable, and understanding the genetic mechanisms contributing to that heritability will improve the application of current drugs while informing the design of new ones (Roden and George, 2002) . Mutations that alter protein structure-coding mutations-are a known cause of that heritability (Hurley et al., 1991) (Figure 1, top) . Meanwhile, non-coding mutations that alter steady-state levels of gene expression are emerging as a major contributor to the heterogeneity of human phenotypes, including drug responsiveness (e.g., Gusev et al., 2014) . For example, genetically altered expression of drug efflux pumps has been shown to contribute to chemotherapeutic resistance in some individuals (Patch et al., 2015) (Figure 1, middle) .
Non-coding mutations are typically thought to act by changing the DNA sequence of TF binding sites in a way that alters the affinity of the TF to those sites (McDaniell et al., 2010) . In this issue, Soccio et al. demonstrate that different alleles of PPARg sites lead to different transcriptional responses to the anti-diabetic drug rosiglitazone (Soccio et al., 2015) (Figure 1 , bottom). In doing so, they recast the PPARg binding sites as drug targets and reveal new ways in which non-coding variants alter disease risk and drug responses. Their findings remarkably expand the realm of personalized medicine, particularly for drugs targeting nuclear receptors.
Mutations in PPARg binding sites are only part of the story. A variety of additional TFs interact with PPARg and contribute to its genomic occupancy. The co-binding TFs each have their own DNA binding preferences, complicating our understanding of how individual noncoding mutations contribute to PPARgmediated effects of rosiglitazone treatment. Soccio et al. show that non-coding genetic variation not only alters PPARg occupancy, but also has coordinated effects on the binding of the associated TFs C/EBP and the glucocorticoid receptor. Furthermore, disruption of the DNA binding sequences of any of those TFs leads to decreased PPARg occupancy. The observed coordinated effects support a model in which TFs bind as a complex on a given allele (ENCODE Proect Consortium, 2012) and indicate that drug response heterogeneity may also result from mutations in binding sites for yet-unknown cooperating TFs. In that manner, it may be more valuable to consider regulatory complexes rather than individual binding sites as the key functional unit for understanding the genetic contributions to PPARg and rosiglitazone responses. Identifying additional members of PPARg regulatory complexes will also likely be valuable for predicting genetic contributions to both type 2 diabetes and its treatment.
While Soccio et al. find a strong enrichment of allele-specific binding sites near rosiglitazone-induced genes, they find no evidence of a similar enrichment near rosiglitazone-repressed genes. The relative challenge of identifying the binding sites responsible for gene repression is a recurring theme in nuclear receptor biology (e.g., Reddy et al., 2009) . One possible explanation is that repressive sites are inherently difficult to assay due to chromatin structure, epitope availability, or indirect interaction with the genome. Alternatively, repression by nuclear receptors may be secondary to activation of direct target genes (Abraham et al., 2006) . Because nearly as many genes are repressed as are activated by nuclear receptors, determining the predominant mechanisms of that repression will be valuable for ongoing efforts to increase the specificity of nuclear receptor drugs. For example, secondary factors may themselves be targets for drugs that are beneficial either alone or in combination with nuclear-receptor-targeting drugs. To realize that potential, a revised understanding of the ways in which nuclear receptors repress gene expression is needed. In particular, determining the relative contribution of each mechanism of repression to the total repressive effects will prioritize the most prevalent mechanisms for subsequent pharmaceutical targeting.
Identifying non-coding variants that alter rosiglitazone's effects in human cells creates a new challenge: how do we determine the resulting organismal effects? The genetic diversity of recombinant inbred mouse strains makes them a powerful resource for linking mouse loci with phenotypes. Protein sequence and function are often conserved between mouse and human, and therefore it is reasonable to hypothesize that mutations in orthologous genes will have similar phenotypic effects. There is now growing evidence that the phenotypic effects of regulatory variation may also be conserved between species (Crowley et al., 2015) . Here, for example, Soccio and colleagues use natural variation in metabolic phenotypes between disparate mouse strains to implicate non-coding variation in PPARg binding sites as contributing to diabetic phenotypes and rosiglitazone responses. They then leverage the conserved structure and function of PPARg between species to identify genetic variants with similar molecular effects in human tissues. Their reliance on conserved TF functions between organisms is an appealing strategy to uncover regulatory mechanisms contributing to type 2 diabetes and one that may generalize broadly to other complex human traits.
Together, the findings of Soccio et al. reveal new mechanisms by which noncoding variation leads to differences in drug responses. Because the genetic variants alter the genomic targets of the drug itself, their findings pave the way to ultimately predict individual transcriptional responses to a prescribed medication. When combined with evidence of which target genes contribute to downstream drug effects, the transcriptional responses may form the basis for new approaches to identify patients who are most or least likely to respond favorably to treatment. 
